Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.78 |
| ▸ | ABL1 | P00519 | 6/20 | 0.77 |
| ▸ | BCR | P11274 | 4/20 | 0.77 |
| ▸ | ABL2 | P42684 | 3/20 | 0.71 |
| ▸ | STK25 | O00506 | 1/20 | 0.71 |
| ▸ | CIT | O14578 | 1/20 | 0.71 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.71 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.71 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.71 |
| ▸ | CASK | O14936 | 1/20 | 0.71 |
| ▸ | GAK | O14976 | 1/20 | 0.71 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.71 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.71 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.71 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.71 |
| ▸ | JAK2 | O60674 | 1/20 | 0.71 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.71 |
| ▸ | ULK1 | O75385 | 1/20 | 0.71 |
| ▸ | PAK3 | O75914 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16626984 | 0.93 | SRC (0.84) | SRCABL1BCRABL2STK25 | |
| SCHEMBL29618203 | 0.90 | SRC (0.85) | SRCABL1BCRABL2STK25 | |
| SCHEMBL2886333 | 0.90 | SRC (0.85) | SRCABL1BCRABL2STK25 | |
| SCHEMBL20655766 | 0.90 | SRC (0.73) | SRCABL1BCRABL2STK25 | |
| SCHEMBL20655762 | 0.90 | SRC (0.73) | SRCABL1BCRABL2STK25 | |
| SCHEMBL20655761 | 0.90 | SRC (0.88) | SRCABL1BCRABL2STK25 | |
| Hydrochloric Acid SCHEMBL19207239 | 0.89 | SRC (0.84) | SRCABL1BCRABL2STK25 | |
| SCHEMBL6182389 | 0.88 | SRC (0.91) | SRCABL1BCRABL2STK25 | |
| SCHEMBL19610518 | 0.88 | SRC (0.82) | SRCABL1BCRABL2STK25 | |
| SCHEMBL6182533 | 0.88 | SRC (1.00) | SRCABL1BCRABL2STK25 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10925967-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10925967-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | BTK, CBL, SYK | SRC 32/4885ABL1 22/4885BCR 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.